A global core outcome measurement set for snakebite clinical trials
Issued Date
2023-02-01
Resource Type
eISSN
2214109X
Scopus ID
2-s2.0-85147046309
Pubmed ID
36669810
Journal Title
The Lancet Global Health
Volume
11
Issue
2
Start Page
e296
End Page
e300
Rights Holder(s)
SCOPUS
Bibliographic Citation
The Lancet Global Health Vol.11 No.2 (2023) , e296-e300
Suggested Citation
Abouyannis M., Esmail H., Hamaluba M., Ngama M., Mwangudzah H., Mumba N., Yeri B.K., Mwalukore S., Alphan H.J., Aggarwal D., Alcoba G., Cammack N., Chippaux J.P., Coldiron M.E., Gutiérrez J.M., Habib A.G., Harrison R.A., Isbister G.K., Lavonas E.J., Martins D., Ribeiro I., Watson J.A., Williams D.J., Casewell N.R., Walker S.A., Lalloo D.G., Walker A.S., Bammigatti C., Carter R.W., Gerardo C.J., de Silva H.J., Lamb T., Lewin M.R., Monteiro W., Stienstra Y. A global core outcome measurement set for snakebite clinical trials. The Lancet Global Health Vol.11 No.2 (2023) , e296-e300. e300. doi:10.1016/S2214-109X(22)00479-X Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82429
Title
A global core outcome measurement set for snakebite clinical trials
Author(s)
Abouyannis M.
Esmail H.
Hamaluba M.
Ngama M.
Mwangudzah H.
Mumba N.
Yeri B.K.
Mwalukore S.
Alphan H.J.
Aggarwal D.
Alcoba G.
Cammack N.
Chippaux J.P.
Coldiron M.E.
Gutiérrez J.M.
Habib A.G.
Harrison R.A.
Isbister G.K.
Lavonas E.J.
Martins D.
Ribeiro I.
Watson J.A.
Williams D.J.
Casewell N.R.
Walker S.A.
Lalloo D.G.
Walker A.S.
Bammigatti C.
Carter R.W.
Gerardo C.J.
de Silva H.J.
Lamb T.
Lewin M.R.
Monteiro W.
Stienstra Y.
Esmail H.
Hamaluba M.
Ngama M.
Mwangudzah H.
Mumba N.
Yeri B.K.
Mwalukore S.
Alphan H.J.
Aggarwal D.
Alcoba G.
Cammack N.
Chippaux J.P.
Coldiron M.E.
Gutiérrez J.M.
Habib A.G.
Harrison R.A.
Isbister G.K.
Lavonas E.J.
Martins D.
Ribeiro I.
Watson J.A.
Williams D.J.
Casewell N.R.
Walker S.A.
Lalloo D.G.
Walker A.S.
Bammigatti C.
Carter R.W.
Gerardo C.J.
de Silva H.J.
Lamb T.
Lewin M.R.
Monteiro W.
Stienstra Y.
Author's Affiliation
Mahidol Oxford Tropical Medicine Research Unit
Université Paris Cité
Department of Medicine
Universidad de Costa Rica
University of Colorado School of Medicine
Organisation Mondiale de la Santé
University College London
Wellcome Trust
Liverpool School of Tropical Medicine
Epicentre
The University of Newcastle, Australia
Hôpitaux Universitaires de Genève
Nuffield Department of Medicine
Medecins Sans Frontieres
Bayero University
MRC Clinical Trials Unit
Drugs for Neglected Diseases Initiative
KEMRI-Wellcome Trust Collaborative Research Programme
Université Paris Cité
Department of Medicine
Universidad de Costa Rica
University of Colorado School of Medicine
Organisation Mondiale de la Santé
University College London
Wellcome Trust
Liverpool School of Tropical Medicine
Epicentre
The University of Newcastle, Australia
Hôpitaux Universitaires de Genève
Nuffield Department of Medicine
Medecins Sans Frontieres
Bayero University
MRC Clinical Trials Unit
Drugs for Neglected Diseases Initiative
KEMRI-Wellcome Trust Collaborative Research Programme
Other Contributor(s)
Abstract
Snakebite clinical trials have often used heterogeneous outcome measures and there is an urgent need for standardisation. A globally representative group of key stakeholders came together to reach consensus on a globally relevant set of core outcome measurements. Outcome domains and outcome measurement instruments were identified through searching the literature and a systematic review of snakebite clinical trials. Outcome domains were shortlisted by use of a questionnaire and consensus was reached among stakeholders and the patient group through facilitated discussions and voting. Five universal core outcome measures should be included in all future snakebite clinical trials—mortality, WHO disability assessment scale, patient-specific functional scale, acute allergic reaction by Brown criteria, and serum sickness by formal criteria. Additional syndrome-specific core outcome measures should be used depending on the biting species. This core outcome measurement set provides global standardisation, supports the priorities of patients and clinicians, enables meta-analysis, and is appropriate for use in low-income and middle-income settings.